Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BMO Capital Downgrades Horizon Therapeutics to Market Perform

BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.
byBenzinga Newsdesk
December 13, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

BMO Capital analyst Gary Nachman downgrades Horizon Therapeutics (NASDAQ:HZNP) from Outperform to Market Perform.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Johnson & Johnson’s Carvykti Stands Ahead Of Bristol Myers’ Rival Blood Cancer Therapy With FDA Approval For Wider Population

By Vandana Singh
April 8, 2:19 PM
FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration efforts.

JNJ